It comes down to economics. That's why nothing can stop

New Post Public Reply Private Reply Replies (1) Message Board
bellsandwhistles
It comes down to economics. That's why nothing can stop suffering patients from seeking out mmj, and why SKTO is in the sweet spot. MMJ reportedly works like a charm, and it's cheap relative to what Big Pharma can offer with the attendant side effects. This piece strongly reinforces that argument.

-- One friend underwent chemotherapy for cervical cancer last year and opted for the legal medicine, which cost around $1,500 per treatment for six treatments, he said. "She underwent the first round, woke up that afternoon, thinking she was going to die.

She said, 'I've never been so frightened in my life, and I remember somebody gave me marijuana,'"

Kuhn said. "She took a puff and, two minutes later, she said, 'I feel fine. I wonder what's for dinner.' So it was $9,000, compared to $50 worth of marijuana. It's an economic issue as well as a compassionate issue."
--

February 06, 2014
In the Weeds

As the Tennessee legislature considers legalizing medical marijuana, those who need it must weigh the risks of breaking the law — or moving out of state.

Mary Foster doesn't remember exactly when she was diagnosed with Alzheimer's, but she remembers she was in her 40s. She's now 52 and retired, and though she may not remember the date of her diagnosis, she remembers why she started smoking marijuana to help relieve her symptoms.

"I was sick, and I was losing a lot of weight," she says. "I had really bad headaches, and I wasn't sleeping."

She's not sure if it was the Alzheimer's itself or a side effect of the medication she was taking, but a friend saw what she was going through and suggested she try marijuana.

"My wife said, 'You know, if that is finally the only thing that's going to help you, I do not approve, but I can't watch you like this anymore,'" Foster says. "She had to go against everything she believed in. It is a divisive issue. It's horrible, in that the benefit is a risk for our family."

State Representative Sherry Jones (D-Nashville) is hoping to change that. She is sponsoring HB 1385 — better known as the Koozer-Kuhn Medical Cannabis Act — currently making its way through the Tennessee General Assembly. It was assigned to the Health Subcommittee on January 15th.

The bill is the latest chapter in the Tennessee medical marijuana story. The most recent prior effort, a 2012 bill sponsored by former Representative Jeanne Richardson (D-Memphis) was withdrawn before it could be put up for a vote.

The qualifying diseases covered in the newly-proposed bill include cancer, glaucoma, multiple sclerosis, HIV, AIDS, Crohn's disease, and Alzheimer's. The main difference between this bill and the one from two years ago is the inclusion of post-traumatic stress disorder. However, the approval process and legality is the same, especially the Safe Access identification card program, in which patients would be required to enroll and receive a card in order to get prescriptions.

Tennessee legislators have rejected medical marijuana legislation time and time again. Former Senator Steve Cohen proposed a similar bill in 2005. And Jones says she has sponsored or co-sponsored medical marijuana bills for six years in the Tennessee House of Representatives to no avail.

"It's the right thing for us to do for people who are suffering needlessly in this state — people with muscular dystrophy, who may have severe muscle spasms; cancer patients, the nausea and the wasting," Jones says. "There are so many diseases that medical marijuana positively affects. It's time for us to get on that train and stop the suffering of as many Tennesseans as we can."

Twenty-one states currently allow legal medical marijuana. And more states are initiating legalization bills. Florida just approved putting medical marijuana on the ballot for 2014.

"I think the public sees that it helps people," Jones says. "My brother had Crohn's disease. He died from the effects of Crohn's disease. He wished that he had been able to have medical cannabis when he was in the hospital the last eight months of his life, dying from the pain and the complications."

Jeanne Kuhn, whom the bill is named for, died in 1996, after a battle with breast cancer. Her husband, Paul Kuhn, of Nashville, is working with the board of the National Organization for the Reform of Marijuana Laws (NORML).

"She was diagnosed with what turned out to be a very aggressive form of breast cancer and underwent three rounds of chemotherapy, an induction course to see if the chemo would respond — which it did, initially," Kuhn says. "Then she went through the most extreme: the high dose of chemo and stem cell transplant, which was a really unpleasant procedure."

The couple discussed supplemental medicine when she began treatment, either taking the legal route with anti-emetics (drugs used to curb nausea and vomiting) or marijuana. After speaking to other patients, her nurses, and her oncologist, Jeanne began to use marijuana.

"It kept her appetite up, kept her spirits up," Kuhn says. "That final round, she said, 'Paul, I smell marijuana and I think of chemo now, so I'm going to use the legal drugs.' She went in for that final round and took the legal drugs. She had been home around 20 minutes, and I could see she was uncomfortable. She said, 'Bring me the damn pot.' She took a puff and the nausea was gone."

In his position at NORML, Kuhn interacts with others affected by ailments that could be relieved with medical marijuana. One friend underwent chemotherapy for cervical cancer last year and opted for the legal medicine, which cost around $1,500 per treatment for six treatments, he said.

"She underwent the first round, woke up that afternoon, thinking she was going to die. She said, 'I've never been so frightened in my life, and I remember somebody gave me marijuana,'" Kuhn said. "She took a puff and, two minutes later, she said, 'I feel fine. I wonder what's for dinner.' So it was $9,000, compared to $50 worth of marijuana. It's an economic issue as well as a compassionate issue."

The Center for Medical Cannabis Research at the University of California at San Diego has, despite discontinuing studies involving cancer patients due to lack of qualified participants, completed some studies regarding the effects of smoked marijuana on various ailments. The center found positive benefits for patients of multiple sclerosis and HIV, while other entities, such as the National Cancer Institute — a government agency — report the significant increase in appetite, decrease in nausea, and effective pain treatment of patients who smoked medical marijuana.

Kuhn says the biggest challenge for the Tennessee bill will be the Republicans in the General Assembly who have historically voted against medical marijuana.

"The support is there. The trouble is the politicians are behind the public," he said. "They never had to think about it. They've just always been opposed to it."

Last year, a Fox News poll found that 85 percent of voters support medical marijuana — statistics Richardson did not have in her arsenal when the 2012 bill was up for committee. Kuhn says the Koozer-Kuhn Medical Cannabis Act is among the strictest in the country.

"The marijuana would be grown under the supervision of the Department of Agriculture and processed under their supervision," Kuhn said. "Farmers would be trained. It would be sold in dispensaries supervised by the Department of Health, so it's got lots of control. You have to get the card, obviously, on a recommendation from the doctor. It would create jobs. It would bring in millions of dollars of revenue to the state."

Kuhn cites the Mattisons, a family from Nashville. Their 2-year-old daughter, Millie, suffers from severe daily seizures, numbering in the hundreds each week.

"She will die without cannabis, there's no doubt about it," Kuhn says.

Millie's parents, Nicole and Penn Mattison, tried everything, including six or seven epileptic prescriptions. The ketogenic diet, which focuses on high fats and low carbs for children with seizures, caused Millie's kidneys to shut down.

"She was on up to 2,000 mg of Sabril [an anticonvulsant] and that was just one of her medications. That is a dose for a full-grown man," Nicole says.

After neurosurgeons at Vanderbilt University told the Mattisons there was nothing else they could do, the family decided to move to Colorado, where medical and recreational pot is legal. They plan to try Charlotte's Web, a strain of marijuana that has been used to treat children with severe seizures. The strain is of the indica variety, which means the cannabis plant has significantly less tetrahydrocannabinol (THC) — the element that actually gets users high — but more cannabinol (CBD) than its counterpart, sativa, which has high THC value and low CBD.

The effectiveness of Charlotte's Web has been debated. Some doctors argue that the strain must be trial-tested like any other drug. Families like the Mattisons says they do not have the luxury of time.

"Charlotte Figi [who the strain is named after] has been on it for two years, and she has been pharmaceutical-free for a year now," Nicole says. "When we look at Millie and what she goes through day-to-day, that's good for us."

The Mattisons might move back to Tennessee if Koozer-Kuhn passes. Nicole already has an idea of how they could contribute — Penn has been involved in horticulture for 22 years, and he is interested in growing medical marijuana. That's way down the road, though.

"Our first concern right now is helping Millie and seeing how far we can get with her," Nicole says.

Different strains of marijuana help different medical conditions. For Foster, it's a strain called Harlequin, a hybrid that is 75 percent sativa.

"People with Alzheimer's benefit from a type that's sativa-dominant, but balanced with CBD, so there needs to be that stimulation from the sativa [as well as] the energizing ability [and] the ability to focus. The CBD needs to be a little lower," Foster says. "It's good for anxiety and keeping an appetite, but that is absolutely impossible to get on the black market here unless you know someone who will take a risk to ship it to you — or you will take a risk to drive, if you have the means."

Alzheimer's patients may also benefit from marijuana's inflammation reduction effects. Foster says it also helps with another side of Alzheimer's: coping.

"It doesn't make me Superwoman, and I can still only do less in more time [than I used to]. It helps me accept my limitations," she says. "I don't push myself as hard. I can forgive myself. It's like my friend who's dying of cancer said to me: 'It doesn't take away the pain as much as it helps me live with it.'"

Joe Roberts*, a construction supervisor, suffered a stroke more than 20 years ago that left the right side of his body mostly paralyzed. He has limited use in his right arm and hand and still suffers pain from the injury.

"I also take over-the-counter pain killers, but pot just seems to cut the pain and makes the day easier to bear," Roberts says.

Roberts, who is over 60, has been smoking marijuana intermittently since college, but the stroke caused him to smoke more frequently. While he is pessimistic about the Tennessee medical marijuana bill passing, Roberts sees the tide turning.

"I think a lot of people, especially as the baby boomers age, know somebody who knows somebody who benefits greatly from medical marijuana," he says.

Back in her home, Foster pulls out a large purple prescription bottle with a green "Rx" on the side. Her name is printed on it, alongside a warning — not to be consumed. It looks official, but there's no way it came from Tennessee. At least, not yet.

Getting her medical marijuana is a fluid affair, changing all the time. It could be a grower from Washington or Colorado with a surplus; it could be a sympathetic friend who's going out of town; or a shady source with illicit ties — good only once. It might be a sativa or an indica, but it's better than nothing, and she remains grateful.

"If I wanted to up my risk level, if I wanted to get something shipped to me, I could do it. I'm not ready to risk that," Foster says. "I just have to put up with what's on the black market. [Some strains are] okay for some things, but [they're] not quite right for others."

She says the way she receives her marijuana is a lot like going to a Walgreens pain reliever aisle, seeing that all the boxes are unlabeled, and randomly selecting one.

"You can get something that has such an incredibly strong medication level that you would barely be able to function if you weren't needing it for pain control," Foster says. "That would not be at all what I need, so I don't like to gamble like that, when it's really about making me function better. But you've got to take a risk."

Foster hopes, with increased awareness of the bill, that more Tennesseans will get involved and other medical marijuana users will step forward with testimonial evidence to educate legislators to medical marijuana's real benefits.

"The people who can be a face on this are people who are willing to lose what they have," Foster says. "Do I have any [pot] in the house? Do I risk being busted? Do I not try and get any until it's legal? These are all huge issues. I do not want to expose myself and my family to liability."

SK3 Group Inc. (SKTO) Stock Research Links

SKTO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 220

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 0

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 90

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 408

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 39

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 208

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 237

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

SoftBank Expands AI Infrastructure with DigitalBridge Deal

Updated Category News Views 109

SoftBank's Strategic Move in AI Infrastructure SoftBank Group Corp. has recently announced its plans to acquire DigitalBridge Group Inc. in a cash deal worth approximately $4 billion. This move is seen as a pivotal step in SoftBank's commitment to scaling its infrastructure capabilities for artificial intelligence globally. Details of the Acquisition Under the terms of...

Continue Reading
Nio's Bold Moves in the EV Space: What Investors Should Know

Updated Category News Views 158

Forget the Noise, Nio's Got a Game Plan Back in my day, when you heard whispers about a new product launch, it was either a cause for celebration or a catastrophe waiting to happen. Nio, the fast-rising EV player from China, is set to drop its ES9 SUV this May, and trust me, eyes are on the road. They’ve laid out the details like a clear roadmap. Mark Your Calendars Qin...

Continue Reading
Graycliff Partners Declares Landmark Structures Sale to Cerberus

Updated Category News Views 166

Graycliff Partners Announces the Sale of Landmark Structures Graycliff Partners LP has revealed its decision to sell Landmark Structures, an esteemed provider of water and industrial storage infrastructure solutions, to Cerberus Capital Management, a robust investment firm with a global reach. Landmark Structures specializes in designing, manufacturing, and installing...

Continue Reading
Wedbush Recognizes Uber Technologies as a Top Investment

Updated Category News Views 229

Wedbush Identifies Uber Technologies as a Prime Investment Opportunity In a recent analysis, Wedbush has included Uber Technologies Inc (NYSE: UBER) in its prestigious 'best ideas list.' This recognition stems from the company's attractive risk/reward dynamics, particularly as its shares are trading at a lower multiple. Valuation Insights Currently, Uber's stock is...

Continue Reading
Ververica Enhances Global Impact Through Innovative Partnerships

Updated Category News Views 161

Ververica's Global Influence in Real-Time Data Streaming Ververica, the pioneers behind Apache Flink®, recently highlighted its expanding global impact during the Flink Forward Jakarta event. This flagship occasion, known for focusing on cutting-edge data streaming technologies, served as an excellent platform for Ververica to demonstrate its dedication to helping...

Continue Reading